Everett E. Vokes to Piperazines
This is a "connection" page, showing publications Everett E. Vokes has written about Piperazines.
Connection Strength
0.343
-
Palbociclib: a new partner for cetuximab? Lancet Oncol. 2019 09; 20(9):1195-1196.
Score: 0.154
-
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 2005 Jan 20; 23(3):585-90.
Score: 0.056
-
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer. 2014 Mar 14; 14:185.
Score: 0.027
-
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 2014 Mar; 13(3):576-84.
Score: 0.026
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.022
-
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23.
Score: 0.019
-
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
Score: 0.019
-
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 2009 Mar; 89(3):301-14.
Score: 0.019